Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 8/20 | 0.48 |
| ▸ | GSK3A | P49840 | 3/20 | 0.46 |
| ▸ | CDKL2 | Q92772 | 1/20 | 0.41 |
| ▸ | MAP2K4 | P45985 | 4/20 | 0.40 |
| ▸ | AAK1 | Q2M2I8 | 6/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.40 |
| ▸ | PIM1 | P11309 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.39 |
| ▸ | GAK | O14976 | 2/20 | 0.39 |
| ▸ | STK16 | O75716 | 2/20 | 0.39 |
| ▸ | BMP2K | Q9NSY1 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16675942 | 0.99 | GSK3B (0.48) | GSK3BGSK3ACDKL2MAP2K4AAK1 | |
| SCHEMBL16675963 | 0.81 | GSK3B (0.48) | GSK3BGSK3ACDKL2MAP2K4AAK1 | |
| SCHEMBL16675964 | 0.81 | GSK3B (0.49) | GSK3BGSK3ACDKL2AAK1PIK3CD | |
| SCHEMBL16675913 | 0.78 | GRM4 (0.42) | CDK2GRM4CYP1A2 | |
| SCHEMBL16675918 | 0.77 | GRM4 (0.43) | CDK2GRM4CYP1A2 | |
| SCHEMBL16675944 | 0.77 | RIPK1 (0.45) | GSK3BGSK3A | |
| SCHEMBL16682166 | 0.76 | CYP2D6 (0.47) | GRM4 | |
| SCHEMBL16675954 | 0.76 | RIPK1 (0.45) | GSK3BGSK3AMAP2K4 | |
| SCHEMBL16682127 | 0.75 | CYP2D6 (0.48) | GRM4 | |
| SCHEMBL16675953 | 0.73 | GSK3B (0.39) | GSK3BGSK3AAAK1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9580391-B2 | Saturated acyl guanidine for inhibition of F1F0-ATPase | LYCERA CORPORATION (US) | 2017-02-28 | — | — | US | disclosed |
| US-9580391-B2 | Saturated acyl guanidine for inhibition of F1F0-ATPase | LYCERA CORPORATION (US) | 2017-02-28 | — | — | US | disclosed |
| US-20150119439-A1 | SATURATED ACYL GUANIDINE FOR INHIBITION OF F1F0-ATPASE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2015-04-30 | — | — | US | disclosed |
| US-20150119439-A1 | SATURATED ACYL GUANIDINE FOR INHIBITION OF F1F0-ATPASE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2015-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119439-A1 | SATURATED ACYL GUANIDINE FOR INHIBITION OF F1F0-ATPASE | ATP5F1A, ATP5F1D, ATP5F1C | GSK3B 4407/4885GSK3A 4056/4885CDKL2 3515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.